CMSC 2018

Gait in Multiple Sclerosis Improved With Dalfampridine Plus Physical Therapy

Gait in Multiple Sclerosis Improved With Dalfampridine Plus Physical Therapy

By

A combination of dalfampridine extended-release and physical therapy (PT) has shown efficacy for improving gait in people with multiple sclerosis

Multiple Sclerosis Pain Common Disruptive Factor in Everyday Activities

Multiple Sclerosis Pain Common Disruptive Factor in Everyday Activities

By

Pain in patients with multiple sclerosis may affect their daily functioning regardless of disease severity.

Medical Cannabis Shows Promise in Treating Symptoms of Multiple Sclerosis

Medical Cannabis Shows Promise in Treating Symptoms of Multiple Sclerosis

By

Differing formulations and ratios of the subjects' medical cannabis regimens have been accounted for, though further information about ratios of CBD and TCH are subject to change due to continued ongoing research.

Dimethyl Fumarate Not Associated With Greater Pain vs Other DMTs in Relapsing-Remitting MS

Dimethyl Fumarate Not Associated With Greater Pain vs Other DMTs in Relapsing-Remitting MS

By

Investigators assessed the effect of disease-modifying treatments on pain in patients with relapsing-remitting multiple sclerosis.

Skin Tone, Race May Be Associated With Multiple Sclerosis Diagnosis

Skin Tone, Race May Be Associated With Multiple Sclerosis Diagnosis

By

The MS and monophasic ADS groups were compared using quantified melanin measurements via the DSM II Colorimeter; self-reported skin tones of fair, medium, olive, or dark; a self-reported race; and skin tone, which was self-reported using 10 numerical panels of color.

Proposed Protocol Taps Occupational Therapist for Assistance With MS Medication Adherence

Proposed Protocol Taps Occupational Therapist for Assistance With MS Medication Adherence

By

The protocol authors propose a more objective method of managing medication adherence through a profile performed by an occupational therapist.

Ozanimod Superior to Interferon for Relapsing Multiple Sclerosis

Ozanimod Superior to Interferon for Relapsing Multiple Sclerosis

By

This study analyzed results from SUNBEAM (ClinicalTrials.gov Identifier: NCT02294058) and RADIANCE (ClinicalTrials.gov Identifier: NCT01628393), 2 double-blind, randomized, phase 3 trials.

Tuberculosis Common in MS Treated With Immunosuppressive Agents

Tuberculosis Common in MS Treated With Immunosuppressive Agents

By

Immunotherapy in multiple sclerosis may increase the risk for conversion from latent to active tuberculosis infection.

Certain Comorbidities More Common in People With Multiple Sclerosis

Certain Comorbidities More Common in People With Multiple Sclerosis

By

The study researchers examined data from the US database of the IMS Health Real World Data Adjudicated Claims between 2011 and 2015.

Alemtuzumab Reduces MRI Disease Activity, Brain Volume Loss in Relapsing-Remitting MS

Alemtuzumab Reduces MRI Disease Activity, Brain Volume Loss in Relapsing-Remitting MS

By

Alemtuzumab is associated with reduced magnetic resonance imaging disease activity and the slowing of brain volume loss over 7 years in patients with relapsing-remitting multiple sclerosis.

Ocrelizumab May Improve Cognition in Patients At Risk for Progressive Multiple Sclerosis

Ocrelizumab May Improve Cognition in Patients At Risk for Progressive Multiple Sclerosis

By

Cognitive impairment is common in patients with multiple sclerosis (MS) and considerably impacts quality of life.

Optimized Urinalysis Reflex Reduces Urine Culture Orders in MS

Optimized Urinalysis Reflex Reduces Urine Culture Orders in MS

By

Due to the increased risk for urinary tract infections (UTIs) in people with MS and similar CNS demyelinating diseases, as well as the tendency of UTIs to trigger more MS flares, the affected population are subject to a large number of unneeded antibiotic prescriptions and asymptomatic bacteriuria treatments.

Fingolimod Improves Multiple Sclerosis Outcomes After Previous DMT Failure

Fingolimod Improves Multiple Sclerosis Outcomes After Previous DMT Failure

By

Brain volume loss was smaller for all groups after treatment with fingolimod.

Ublituximab Associated With Significant Reduction in MS Disease Activity, Focal Lesions

Ublituximab Associated With Significant Reduction in MS Disease Activity, Focal Lesions

By

TG1101-RMS201 was a multicenter, placebo-controlled, phase 2, 52-week study designed to evaluate the optimal infusion and safety of ublituximab for relapsing multiple sclerosis.

Ocrelizumab Decreases Humoral Response to 4 Vaccines in Multiple Sclerosis

Ocrelizumab Decreases Humoral Response to 4 Vaccines in Multiple Sclerosis

By

The VELOCE trial (ClinicalTrials.gov Identifier: NCT02545868) was an open-label, randomized, phase 3b study designed to assess whether ocrelizumab could raise the humoral responses to vaccines in individuals with relapsing multiple sclerosis.

Risk for Multiple Sclerosis Relapse Low in Transition From Natalizumab to Dimethyl Fumarate

Risk for Multiple Sclerosis Relapse Low in Transition From Natalizumab to Dimethyl Fumarate

By

This retrospective cohort study sought to assess the outcomes for individuals with multiple sclerosis who transitioned from natalizumab to dimethyl fumarate.

MS Relapse, EDSS Score Predict Long-Term Clinical Outcomes

MS Relapse, EDSS Score Predict Long-Term Clinical Outcomes

By

The multiple-logistic regression analyses determined that the most consistent predictors for negative clinical outcomes in months 12 to 48 were relapses during months 0 to 12 and EDSS scores at baseline and months 0 to 12.

Long-Term Teriflunomide for MS Not Associated With Grade 3 Lymphopenia

Long-Term Teriflunomide for MS Not Associated With Grade 3 Lymphopenia

By

Analysis of yearly lymphocyte counts showed a declining occurrence of all grades of lymphopenia over time, and by year 9, subjects exhibited no cases of lymphopenia.

Obesity Associated With Greater Relapse Activity, Impaired Function in MS

Obesity Associated With Greater Relapse Activity, Impaired Function in MS

By

The investigators examined the association between obesity and the age of first symptom(s), number of impaired functional domains, and early relapse activity in patients with MS.

Depression, Fatigue Predict Adherence to Multiple Sclerosis Therapies

Depression, Fatigue Predict Adherence to Multiple Sclerosis Therapies

By

Patients with higher rates of depression and fatigue were significantly more likely to have lower MMAS-8 adherence scores.

Twice-Weekly Interferon Beta-1a Effective for Reducing MS Relapse

Twice-Weekly Interferon Beta-1a Effective for Reducing MS Relapse

By

A prospective, blinded, randomized trial comparing once-weekly and twice-weekly IM IFNβ-1a may be indicated.

Association Between Vitamin D Supplementation, Multiple Sclerosis Relapse Still Unclear

Association Between Vitamin D Supplementation, Multiple Sclerosis Relapse Still Unclear

By

Although the study demonstrated a lower relapse rate among patients with MS who supplemented their diet with vitamin D, the analysis did not reach statistical significance.

Long-Term Efficacy of Alemtuzumab Sustained Without Continuous Treatment in RRMS

Long-Term Efficacy of Alemtuzumab Sustained Without Continuous Treatment in RRMS

By

Investigators explored the efficacy and safety of alemtuzumab in patients initially assigned to alemtuzumab in a previous trial followed by alemtuzumab treatment over a 2-year period in a core study plus an additional 4-year period in an extension trial.

Sign Up for Free e-newsletters



CME Focus